This trial is evaluating whether Alemtuzumab will improve 1 primary outcome and 15 secondary outcomes in patients with Sickle Cell Disease (SCD). Measurement will happen over the course of Day 42.
This trial requires 58 total participants across 1 different treatment group
This trial involves a single treatment. Alemtuzumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"In this group of children, anemia was a common finding which was caused by a variety of hematologic agents. Recent findings further support the concept that anemia is a multifactor etiology which is best investigated in terms of what causes the anemia." - Anonymous Online Contributor
"A combination of signs and symptoms of anemia, particularly fatigue, may be evident in children who are at risk of developing anemia. This condition is caused by the sickle cell gene." - Anonymous Online Contributor
"Anemia, sickle cell disorder, affects at least 5% of African-American patients and causes profound effects on the life of those affected. The treatment of the anemia in individuals with sickle cell should be emphasized." - Anonymous Online Contributor
"In 2013, 5.3 million adults aged 19 and older had [sickle cell anemia](https://www.withpower.com/clinical-trials/sickle-cell-anemia). In the United States, anemia was present in 8.6% of children and adolescents ages 5 to 19 years. In the United States, 6.5% of children and adolescents ages 5 to 19 years are sickle cell trait carriers." - Anonymous Online Contributor
"In addition to supportive therapies, specific therapies like packed red blood cell transfusions and blood transfusions can be necessary when anemia causes severe disability or symptoms." - Anonymous Online Contributor
"In terms of cure rates, HBA > 9g/dL and HbA > 12g/dL may be ideal to seek for patients with SCD and sickle cell anemia." - Anonymous Online Contributor
"Although the data presented during this Symposium show that the use of alemtuzumab is feasible and safe in clinical trials, our knowledge of what alemtuzumab does or looks like and how it affects the body remains limited. More importantly, for clinical use, we have found that our studies have yet to demonstrate benefit for patients with the refractory form of acute myelogenous leukemia after treatment with alemtuzumab. We also have found that while alemtuzumab has a very favorable safety profile, patients with this disease should follow the current recommendations for use of alemtuzumab with caution." - Anonymous Online Contributor
"Results from a recent paper support the concept that anemia and its associated diseases affect a complex interplay among several genetic, behavioral, and environmental factors that are likely to be strongly influenced by family socioeconomic exposures." - Anonymous Online Contributor
"The anemia of thalassemia and sickle cell disease is difficult to control. Patients with severe anemia must be given regular blood therapy to restore platelet counts and hemoglobin levels to normal. The current standard to treat sickle cell disease is-splenectomy. For patients with thalassemia-splenectomy should be deferred for 6 months after a regular course of blood transfusions. For patients who require regular transfusions, they should be treated with prophylactic antimicrobial prophylaxis. There is no cure for anemia." - Anonymous Online Contributor
"Sickle cell disease is mostly the result of genetic mutations and environmental insults. In the United States, one of the most common causes is the exposure of infants to sickle cell disease (Hb S). Other diseases affecting infants such as HIV infection and hepatitis B make the newborns even more vulnerable to sickle cell disease.\n" - Anonymous Online Contributor
"We found that the most common side effects related to alemtuzumab treatment could mostly be sorted in infusion reactions such as pruritus, anaphylactoid reactions, asymeremia, and febrile reactions. In addition, we also found that most patients suffered from diarrhoea and pain. Furthermore, a decrease in hemoglobin levels was observed in some patients during treatment; thus, anaemia needs to be carefully monitored during adjuvant alemtuzumab therapy. In this regard, treatment interruptions should be considered." - Anonymous Online Contributor
"The incidence of side effects such as the FDA-defined grade 2 and 3 AEs, the need to suspend a trial due to adverse events following the initial announcement of AEs, and the proportion of patients who stopped therapy due to these AEs were similar between alemtuzumab and Rituximab. Anecdotal evidence of other anti-IL-2 therapies that have led to greater AE reporting than alemtuzumab include infusions of alemtuzumab from the same batch or alemtuzumab from a different batch. Both sources of infusion experience similar AE reporting and are unlikely to be causative." - Anonymous Online Contributor